IVERIC bio Crescita futura

Future criteri di controllo 5/6

IVERIC bio prevede che gli utili e i ricavi cresceranno rispettivamente di 59% e 58% all'anno. Si prevede che l'EPS crescerà di 61.5% all'anno. Si prevede che il ritorno sul capitale proprio sarà di -21.7% in 3 anni.

Informazioni chiave

59.0%

Tasso di crescita degli utili

61.5%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	28.3%
Tasso di crescita dei ricavi	58.0%
Rendimento futuro del capitale proprio	-21.7%
Copertura analitica	Good
Ultimo aggiornamento	23 Jun 2023

Aggiornamenti recenti sulla crescita futura

Recent updates

Iveric drives Apellis lower as Street reacts to Phase 3 data for GA candidate

Sep 06

IVERIC bio Q2 2022 Earnings Preview

Jul 25

Iveric bio pay DelSiTech €1.25M upfront to develop new formulations of eye disorder drug Zimura

Jul 05

IVERIC bio: A First Take

Jun 23

We're Hopeful That IVERIC bio (NASDAQ:ISEE) Will Use Its Cash Wisely

May 20

Here's Why We're Not Too Worried About IVERIC bio's (NASDAQ:ISEE) Cash Burn Situation

Feb 01

Here's Why We're Not Too Worried About IVERIC bio's (NASDAQ:ISEE) Cash Burn Situation

Jul 02

IVERIC bio discusses GATHER2 enrollment and retention updates and new GATHER1 post-hoc analyses

Jun 18

IVERIC bio EPS misses by $0.04

May 05

We're Hopeful That IVERIC bio (NASDAQ:ISEE) Will Use Its Cash Wisely

Mar 12

We Think IVERIC bio (NASDAQ:ISEE) Can Afford To Drive Business Growth

Nov 27

IVERIC bio EPS misses by $0.05

Nov 02

Previsioni di crescita degli utili e dei ricavi

NasdaqGS:ISEE - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2025	365	-28	57	N/A	9
12/31/2024	124	-200	-131	-154	9
12/31/2023	11	-281	-212	-236	8
3/31/2023	N/A	-223	-178	-177	N/A
12/31/2022	N/A	-185	-165	-164	N/A
9/30/2022	N/A	-159	-138	-137	N/A
6/30/2022	N/A	-141	-123	-122	N/A
3/31/2022	N/A	-122	-107	-107	N/A
12/31/2021	N/A	-115	-99	-99	N/A
9/30/2021	N/A	-107	-97	-97	N/A
6/30/2021	N/A	-108	-86	-86	N/A
3/31/2021	N/A	-96	-78	-78	N/A
12/31/2020	N/A	-85	-66	-66	N/A
9/30/2020	N/A	-77	-57	-57	N/A
6/30/2020	N/A	-66	-54	-54	N/A
3/31/2020	N/A	-61	-51	-51	N/A
12/31/2019	N/A	-59	-48	-48	N/A
9/30/2019	N/A	63	-47	-47	N/A
6/30/2019	N/A	62	-45	-45	N/A
3/31/2019	N/A	64	-44	-44	N/A
12/31/2018	N/A	63	-42	-42	N/A
9/30/2018	N/A	-51	-45	-45	N/A
6/30/2018	207	153	-50	-50	N/A
3/31/2018	208	144	-72	-72	N/A
12/31/2017	210	114	-122	-122	N/A
9/30/2017	215	57	-142	-141	N/A
6/30/2017	10	-192	-132	-131	N/A
3/31/2017	37	-200	-134	-133	N/A
12/31/2016	51	-193	N/A	-109	N/A
9/30/2016	50	-163	N/A	-115	N/A
6/30/2016	52	-141	N/A	-133	N/A
3/31/2016	26	-149	N/A	-84	N/A
12/31/2015	52	-106	N/A	-79	N/A
9/30/2015	48	-102	N/A	-29	N/A
6/30/2015	85	-54	N/A	-50	N/A
3/31/2015	83	-89	N/A	96	N/A
12/31/2014	41	-117	N/A	111	N/A
9/30/2014	40	-106	N/A	75	N/A
6/30/2014	N/A	-132	N/A	107	N/A
3/31/2014	N/A	-71	N/A	-61	N/A
12/31/2013	N/A	-57	N/A	-49	N/A
9/30/2013	N/A	-42	N/A	-27	N/A
6/30/2013	N/A	-30	N/A	-18	N/A
3/31/2013	N/A	-23	N/A	-13	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che ISEE diventerà redditizio nei prossimi 3 anni, il che è considerato una crescita più rapida del tasso di risparmio ( 2.1% ).

Guadagni vs Mercato: Si prevede che ISEE diventerà redditizia nei prossimi 3 anni, il che è considerato una crescita superiore alla media del mercato.

Guadagni ad alta crescita: Si prevede ISEE diventerà redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di ISEE ( 58% all'anno) crescerà più rapidamente del mercato US ( 8.9% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di ISEE ( 58% all'anno) crescerà più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che ISEE non sarà più redditizia tra 3 anni.

IVERIC bio Crescita futura

Future criteri di controllo 5/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Consensus EPS estimates fall by 12%

Forecast to breakeven in 2025

Price target increased by 10% to US$35.09

Forecast to breakeven in 2025

Consensus revenue estimates fall by 13%

No longer forecast to breakeven

Recent updates

IVERIC bio, Inc. Announces Positive 24-Month Topline Results from Phase 3 Study of IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy

European Medicines Agency Accepts Iveric Bio's Marketing Authorization Application for Avacincaptad Pegol for Geographic Atrophy

Iveric Bio Receives U.S. FDA Approval for IZERVAY™ (avacincaptad pegol intravitreal solution), a New Treatment for Geographic Atrophy

IVERIC bio, Inc. Files Form 15

IVERIC bio, Inc.(NasdaqGS:ISEE) dropped from NASDAQ Composite Index

IVERIC bio's Common Stock Delisted from NASDAQ

Senior VP & COO exercised options and sold US$730k worth of stock

Senior VP & COO notifies of intention to sell stock

Consensus EPS estimates fall by 12%

Forecast to breakeven in 2025

Senior VP exercised options and sold US$2.2m worth of stock

Price target increased by 10% to US$35.09

Forecast to breakeven in 2025

Senior VP notifies of intention to sell stock

Senior VP & COO exercised options and sold US$940k worth of stock

Consensus revenue estimates fall by 13%

Senior VP & COO exercised options and sold US$299k worth of stock

No longer forecast to breakeven

Senior VP & COO exercised options and sold US$314k worth of stock

IVERIC bio, Inc. Announces U.S. Food and Drug Administration Accepts New Drug Application for Avacincaptad Pegol for the Treatment of Geographic Atrophy

Senior VP & COO notifies of intention to sell stock

CEO & Director exercised options and sold US$350k worth of stock

Iveric Bio Announces the Addition of Pravin U. Dugel to Its Board of Directors

Forecast to breakeven in 2025

Iveric Bio, Inc. Announces Completion of Rolling NDA Submission to FDA for Avacincaptad Pegol for the Treatment of Geographic Atrophy

Senior VP & COO exercised options and sold US$259k worth of stock

Senior VP & COO exercised options to buy US$109k worth of stock.

IVERIC bio, Inc. has completed a Follow-on Equity Offering in the amount of $300.375 million.

President exercised options to buy US$179k worth of stock.

IVERIC bio, Inc. Announces FDA Has Granted Breakthrough Therapy Designation for Avacincaptad Pegol for Geographic Atrophy

Price target increased to US$30.17

Senior VP & COO exercised options and sold US$964k worth of stock

IVERIC bio, Inc. Announces Submission of First Part of NDA for Rolling Review of Avacincaptad Pegol for the Treatment of Geographic Atrophy

IVERIC bio, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Iveric Bio Announces Positive Topline Data from Zimura® Gather2 Phase 3 Clinical Trial in Geographic Atrophy

Price target increased to US$26.36

Iveric drives Apellis lower as Street reacts to Phase 3 data for GA candidate

Senior VP & Chief Commercial Officer exercised options and sold US$138k worth of stock

IVERIC bio Q2 2022 Earnings Preview

IVERIC bio, Inc. to Report Q2, 2022 Results on Jul 26, 2022

Iveric Bio Announces Post-Hoc Analysis from GATHER1 Clinical Trial of Zimura® At American Society of Retina Specialists Meeting

Insider exercised options and sold US$73k worth of stock

Iveric bio pay DelSiTech €1.25M upfront to develop new formulations of eye disorder drug Zimura

IVERIC bio, Inc.(NasdaqGS:ISEE) dropped from Russell Microcap Value Index

IVERIC bio: A First Take

Independent Director recently bought US$241k worth of stock

IVERIC bio, Inc. Announces Presentation of Post-Hoc Analysis At Macula Society from Gather1 Clinical Trial of Zimura® in Patients with Geographic Atrophy

We're Hopeful That IVERIC bio (NASDAQ:ISEE) Will Use Its Cash Wisely

Price target increased to US$24.38

IVERIC bio, Inc. Completes Retrospective Review of Choroidal Neovascularization

IVERIC bio, Inc., Annual General Meeting, May 12, 2022

Senior VP exercised options and sold US$261k worth of stock

Senior VP notifies of intention to sell stock

IVERIC bio, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Iveric Bio Announces Foveal Anatomy Post-Hoc Analysis from GATHER1 Clinical Trial of Zimura® in Patients with Geographic Atrophy

Here's Why We're Not Too Worried About IVERIC bio's (NASDAQ:ISEE) Cash Burn Situation

IVERIC bio, Inc. Announces in GATHER2, the Company's Phase 3 Clinical Trial Evaluating the Safety and Efficacy of Zimura (Avacincaptad Pegol) for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration

CEO & Director exercised options and sold US$882k worth of stock

CEO & Director exercised options and sold US$122k worth of stock

Insider recently bought US$50k worth of stock

IVERIC bio (NASDAQ:ISEE) Is In A Good Position To Deliver On Growth Plans

Estimating The Intrinsic Value Of IVERIC bio, Inc. (NASDAQ:ISEE)

Apellis' Loss Is Iveric Bio's Gain In Lucrative Eye Disease Field

Price target increased to US$16.50

IVERIC Bio, Inc. Provides Updates on Clinical Trails

Here's Why We're Not Too Worried About IVERIC bio's (NASDAQ:ISEE) Cash Burn Situation

Price target increased to US$14.67

IVERIC bio, Inc. Updates on Its Phase 3 Clinical Trails Zimura

IVERIC bio discusses GATHER2 enrollment and retention updates and new GATHER1 post-hoc analyses